Particle.news
Download on the App Store
5 ARTICLES
·
last wk.

Merck and Mayo Clinic Launch AI Drug Discovery Collaboration Using Platform_Orchestrate

The deal gives Merck in-platform access to de-identified clinical, imaging, genomic records to train and validate AI models.

The partnership gives MSD access to datasets, registries, biorepositories, AI tools, analytics, and scalable solutions via Mayo Clinic. Credit: ART STOCK CREATIVE / Shutterstock.com.

Overview

  • The partners will begin with three priorities: inflammatory bowel disease, atopic dermatitis and multiple sclerosis.
  • Merck will run its models inside Mayo Clinic’s secure Platform_Orchestrate environment, accessing registries, biorepositories, advanced AI tools and scalable analytics rather than receiving a static data dump.
  • Merck plans to apply AI and machine learning, including its virtual cell technologies, to deepen disease understanding, improve target identification and inform early development decisions.
  • Mayo Clinic describes this as its first collaboration of this scale with a global biopharmaceutical company, aligning with Merck’s wider investments in AI-enabled discovery.
  • The collaboration has been announced and initiated with data integration and model validation activities underway, with no research findings reported to date and customary forward‑looking cautions noted.